Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.

Manish A ShahPeter EnzingerAndrew H KoAllyson J OceanPhilip Agop PhilipPrashant V ThakkarKyle ClevelandYao LuJeremy KortmanskyPaul J ChristosChao ZhangNavjot KaurDina ElmonshedGiuseppe GallettiSandipto SarkarBhavneet BhinderMeredith E Pittman Olga Mikhaylovna Plotnikova Nikita Kotlov Felix E Frenkel Alexander V BagaevOlivier ElementoDoron BetelParaskevi GiannakakouHeinz-Josef Lenz

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Cabazitaxel has modest activity in advanced gastric cancer, including in patients previously treated with taxanes. Her2 amplification/overexpression and M2 high macrophage signature are potential biomarkers for taxane efficacy that warrant further evaluation.

Keyphrases

phase ii study
end stage renal disease
newly diagnosed
ejection fraction
poor prognosis

chronic kidney disease
open label
adipose tissue
locally advanced
papillary thyroid

neoadjuvant chemotherapy
case report
squamous cell carcinoma
cell proliferation
long non coding rna

patient reported outcomes
radiation therapy
binding protein
rectal cancer